LSE:OKYO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OKYO Pharma Limited operates as a life sciences and biotechnology company in the United Kingdom.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has OKYO Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OKYO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

114.3%

OKYO

-2.8%

GB Biotechs

2.2%

GB Market


1 Year Return

87.5%

OKYO

15.0%

GB Biotechs

-10.0%

GB Market

Return vs Industry: OKYO exceeded the UK Biotechs industry which returned 15% over the past year.

Return vs Market: OKYO exceeded the UK Market which returned -10% over the past year.


Shareholder returns

OKYOIndustryMarket
7 Day114.3%-2.8%2.2%
30 Day59.6%7.9%9.6%
90 Day177.8%12.1%-2.6%
1 Year87.5%87.5%16.0%15.0%-5.7%-10.0%
3 Year15.4%15.4%30.3%27.8%-1.8%-13.8%
5 Year-28.6%-28.6%48.4%44.6%15.5%-10.2%

Price Volatility Vs. Market

How volatile is OKYO Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OKYO Pharma undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether OKYO Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as OKYO Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is OKYO Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OKYO Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of OKYO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • OKYO Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has OKYO Pharma performed over the past 5 years?

-25.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OKYO is currently unprofitable.

Growing Profit Margin: OKYO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OKYO is unprofitable, and losses have increased over the past 5 years at a rate of -25.9% per year.

Accelerating Growth: Unable to compare OKYO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OKYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: OKYO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is OKYO Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: OKYO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: OKYO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: OKYO is debt free.

Reducing Debt: OKYO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OKYO has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: OKYO is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is OKYO Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OKYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OKYO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OKYO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OKYO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OKYO's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average board tenure


CEO

OKYO Pharma has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Willy Simon
Acting Chairman2.58yrsno datano data
Kunwar Shailubhai
Independent Non-Executive Director2.92yrsno datano data
Gregor Charles MacRae
Non Executive Director0.50yrno datano data

2.6yrs

Average Tenure

61yo

Average Age

Experienced Board: OKYO's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.


Top Shareholders

Company Information

OKYO Pharma Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OKYO Pharma Limited
  • Ticker: OKYO
  • Exchange: LSE
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£25.218m
  • Shares outstanding: 672.47m
  • Website: https://www.okyopharma.com

Number of Employees


Location

  • OKYO Pharma Limited
  • 55 Park Lane
  • London
  • Greater London
  • W1K 1NA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OKYOLSE (London Stock Exchange)YesOrdinary SharesGBGBPJul 2008

Biography

OKYO Pharma Limited operates as a life sciences and biotechnology company in the United Kingdom. Its development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM-8, a non-opiod analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 22:36
End of Day Share Price2020/06/05 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.